Date: April 3, 2023

To,

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street,

Mumbai - 400 001

To,

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G

Bandra Kurla Complex

Bandra (E), Mumbai - 400 051

Subject: Disclosure under Regulation 29 (2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Reference: Supriya Lifescience Limited Scrip Code: 543434

Dear Sir/Madam,

With reference to the above captioned matter, please find enclosed herewith, disclosure under Regulation 29 (2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the acquisition made on March 31, 2023.

You are requested to take the same on your records.

Thanking You,

Yours Faithfully,

Dr. Satish Wagh

cc to:

The Company Secretary and Compliance Officer Supriya Lifescience Limited 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400063.

ANNEXURE - 1

Format for Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Supriya Lifescience Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Dr. Satish Wagh		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	 National Stock Exchange of India Ltd. BSE Ltd. 		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of:			
 a) Shares carrying voting rights b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others) 	54428205	67.627	67.627
 Voting rights (VR) otherwise than by equity shares 			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
e) Total (a+b+c+d)			**************************************

Details	of acquisition/sale			
a) b)	Shares carrying voting rights acquired/sold VRs acquired/sold otherwise than by equity shares	13,000	0.016	0.016
c)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying			
d)	voting rights in the TC (specify holding in each category) acquired/sold Shares encumbered / invoked/released by the acquirer			
e)	Total (a+b+c+/-d)			
After t	he acquisition/sale, holding of :			
a) b) c)	Shares carrying voting rights Shares encumbered with the acquirer VRs otherwise than by shares	54441205	67.643	67.643
d)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
e)	Total (a+b+c+d)	_		
off-mar	f acquisition / sale (e.g. open market / ket / public issue / rights issue ntial allotment / inter-se transfer etc).	Open Market		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable		31.03.2023		

Equity share capital / total voting capital of the TC before the said acquisition / sale	Rs. 16,09,65,600/- (8,04,82,800 Equity Shares of Rs. 2/- each)	
Equity share capital/total voting capital of the TC after the said acquisition / sale	Rs. 16,09,65,600/- (8,04,82,800 Equity Shares of Rs. 2/- each)	
Total diluted share/voting capital of the TC after the said acquisition	Rs. 16,09,65,600/- (8,04,82,800 Equity Shares of Rs. 2/- each)	

Note:

- (*) Total share capital/voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.
- (**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Dr. Satish Wagh

Place: Mumbai

Date: 03.04.2023